The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice.
作者信息
Sandborn William J, Feagan Brian G, Hanauer Stephen B, Lichtenstein Gary R
出版信息
Gastroenterol Hepatol (N Y). 2021 Apr;17(4 Suppl 4):3-13.
Abstract
摘要
相似文献
1
The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice.
Gastroenterol Hepatol (N Y). 2021 Apr;17(4 Suppl 4):3-13.
2
The lived experience of adults with ulcerative colitis.
J Clin Nurs. 2015 Sep;24(17-18):2659-67. doi: 10.1111/jocn.12892. Epub 2015 Jun 25.
3
Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients.
Dig Endosc. 2016 Apr;28(3):260-5. doi: 10.1111/den.12505. Epub 2015 Jul 26.
4
Clinical trials in ulcerative colitis: a historical perspective.
J Crohns Colitis. 2015 Jul;9(7):580-8. doi: 10.1093/ecco-jcc/jjv074. Epub 2015 Apr 25.
5
[Adalimumab for the treatment of ulcerative colitis--a consensus report by the working group inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology].
Z Gastroenterol. 2014 Feb;52(2):204-11. doi: 10.1055/s-0033-1355818. Epub 2014 Jan 31.
6
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD011450. doi: 10.1002/14651858.CD011450.pub2.
7
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
Inflamm Bowel Dis. 2006 Oct;12(10):972-8. doi: 10.1097/01.mib.0000231496.92013.85.
8
Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey.
Gastroenterol Hepatol. 2019 Feb;42(2):90-101. doi: 10.1016/j.gastrohep.2018.09.002. Epub 2018 Oct 4.
9
Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis.
J Crohns Colitis. 2014 Jan;8(1):1-4. doi: 10.1016/j.crohns.2013.10.006. Epub 2013 Nov 12.
10
Guidelines for the treatment of ulcerative colitis in remission.
Eur J Gastroenterol Hepatol. 1997 Sep;9(9):836-41. doi: 10.1097/00042737-199709000-00003.
引用本文的文献
1
Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice.
World J Gastroenterol. 2025 Aug 7;31(29):107745. doi: 10.3748/wjg.v31.i29.107745.
2
Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis.
Patient Prefer Adherence. 2024 Apr 10;18:809-820. doi: 10.2147/PPA.S446861. eCollection 2024.
3
Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000.
Sci Rep. 2023 Aug 21;13(1):13555. doi: 10.1038/s41598-023-40624-5.
4
Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.
Am J Gastroenterol. 2023 Nov 1;118(11):1940-1953. doi: 10.14309/ajg.0000000000002404. Epub 2023 Jun 12.
5
Living With Inflammatory Bowel Disease: Online Surveys Evaluating Patient Perspectives on Treatment Satisfaction and Health-Related Quality of Life.
Crohns Colitis 360. 2022 Sep 20;4(3):otac035. doi: 10.1093/crocol/otac035. eCollection 2022 Jul.
6
Evidence-based pathogenesis and treatment of ulcerative colitis: A causal role for colonic epithelial hydrogen peroxide.
World J Gastroenterol. 2022 Aug 21;28(31):4263-4298. doi: 10.3748/wjg.v28.i31.4263.
7
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
Front Med (Lausanne). 2022 Jun 15;9:897936. doi: 10.3389/fmed.2022.897936. eCollection 2022.
8
How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease.
J Clin Med. 2022 Feb 4;11(3):829. doi: 10.3390/jcm11030829.
本文引用的文献
1
Early Intervention in Ulcerative Colitis: Ready for Prime Time?
J Clin Med. 2020 Aug 14;9(8):2646. doi: 10.3390/jcm9082646.
2
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1366-1376.e2. doi: 10.1016/j.cgh.2020.07.012. Epub 2020 Jul 12.
3
First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
Curr Gastroenterol Rep. 2020 Jan 30;22(2):7. doi: 10.1007/s11894-020-0745-y.
4
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.
Gastroenterology. 2020 Apr;158(5):1450-1461. doi: 10.1053/j.gastro.2020.01.006. Epub 2020 Jan 13.
5
AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.
Gastroenterology. 2020 Apr;158(5):1465-1496.e17. doi: 10.1053/j.gastro.2020.01.007. Epub 2020 Jan 13.
6
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2244-2255.e9. doi: 10.1016/j.cgh.2019.11.059. Epub 2019 Dec 7.
7
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
8
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
J Crohns Colitis. 2020 Feb 10;14(2):254-266. doi: 10.1093/ecco-jcc/jjz131.
9
Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
Gastrointest Endosc Clin N Am. 2019 Jul;29(3):421-436. doi: 10.1016/j.giec.2019.02.004. Epub 2019 Apr 6.
10
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.
Am J Gastroenterol. 2019 Jun;114(6):874-883. doi: 10.14309/ajg.0000000000000183.
Zotero 插件